- Trials with a EudraCT protocol (34,451)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
34,451 result(s) found for: No treatment.
Displaying page 187 of 1,723.
EudraCT Number: 2005-003251-13 | Sponsor Protocol Number: D1449L00002 | Start Date*: 2005-10-20 |
Sponsor Name:AstraZeneca UK Ltd | ||
Full Title: Quetiapine Augmentation In Treatment-Resistant Depression – An Open Pilot Study | ||
Medical condition: Depression | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004796-11 | Sponsor Protocol Number: CZOL446GDE24 | Start Date*: 2007-08-14 |
Sponsor Name:Klinikum Augsburg | ||
Full Title: An Open-Label, Non-Randomized, Single center Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PgR+ Breast... | ||
Medical condition: Prevention of cancer treatment-related bone loss in postmenopausal women with resected stage I-IIIa hormone receptor positive breast cancer, who will receive letrozole as adjuvant therapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001083-43 | Sponsor Protocol Number: BAY 59-7939 / 11223 | Start Date*: 2004-11-23 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis ODIXa-DVT A prospective, randomized, multinational, multicenter, partially blinded, parallel-grou... | |||||||||||||
Medical condition: Acute deep vein thrombosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014580-39 | Sponsor Protocol Number: SP-B-02 | Start Date*: 2010-01-05 | |||||||||||
Sponsor Name:ALK-Abelló Arzneimittel GmbH | |||||||||||||
Full Title: A multicentre randomised Phase II clinical pilot study to compare the pharmacodynamic efficacy and tolerability of the sublingual and the vestibular administration route for SLITonePLUS® Birch | |||||||||||||
Medical condition: Birch pollen induced allergic rhinoconjunctivitis requiring treatment during the birch pollen season | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-018005-43 | Sponsor Protocol Number: 205.419 | Start Date*: 2010-06-14 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 μg once ... | |||||||||||||
Medical condition: Moderate persistent asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003239-31 | Sponsor Protocol Number: HOVIR_700 | Start Date*: 2014-03-14 |
Sponsor Name:HOV GmbH | ||
Full Title: A randomised, placebo-controlled, single-centre, double-blind study to evaluate the efficacy, safety and tolerability of topically applied piroxicam gel in patients with recurrent herpes labialis | ||
Medical condition: Recurrent Herpes labialis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Temporarily Halted) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019411-37 | Sponsor Protocol Number: FE999906CS11 | Start Date*: 2010-08-30 | |||||||||||
Sponsor Name:FERRING Arzneimittel GmbH | |||||||||||||
Full Title: A Prospective, Open Label, Randomised, Parallel Group Trial Comparing the Effects of Highly Purified Menotrophin and Recombinant Follicle Stimulating Hormone (rFSH, Follitropin alpha) Administered ... | |||||||||||||
Medical condition: Controlled ovarian hyperstimulation to induce the development of multiple follicles for assisted reproductive technologies | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004579-35 | Sponsor Protocol Number: A3921095 | Start Date*: 2012-05-01 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, New York 10017 | |||||||||||||
Full Title: A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | |||||||||||||
Medical condition: Moderate to severe active Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) HU (Completed) EE (Completed) DK (Completed) LV (Completed) BE (Completed) ES (Completed) NL (Completed) AT (Completed) DE (Completed) SK (Completed) PL (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005542-35 | Sponsor Protocol Number: CRFB002DDE21 | Start Date*: 2012-05-08 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: Multicenter randomized open-label three-arms controlled 12 months clinical proof of concept study to evaluate efficacy and safety of Ranibizumab alone or in combination with laser photocoagulation ... | |||||||||||||
Medical condition: Proliferative diabetic retinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004775-36 | Sponsor Protocol Number: DETOX-11 | Start Date*: 2012-01-30 | |||||||||||
Sponsor Name:GET SRL | |||||||||||||
Full Title: ''A Phase III, multicenter, open-label study, to evaluate the efficacy and safety of different dosage regimens of 0.2 mg lofexidine hydrochloride (DIMATEX) in the treatment of withdrawal symptoms d... | |||||||||||||
Medical condition: Oppiate addicts(heroin, methadone and buprenorphine) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004455-52 | Sponsor Protocol Number: CP15/15 | Start Date*: 2016-04-18 |
Sponsor Name:Cipla Europe NV | ||
Full Title: An open label, prospective, randomized, parallel group, multicenter 4-week study to evaluate the efficacy and safety of salmeterol/ fluticasone propionate fixed dose combination following ... | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002650-67 | Sponsor Protocol Number: IBERepic/2018 | Start Date*: 2018-11-15 |
Sponsor Name:Ibermutuamur (Mutua Colaboradora con la Seguridad Social nº 274) | ||
Full Title: Comparison of the efficacy of autologous platelet rich plasma injections, and extracorporeal shock wave therapy, in the treatment of work –related lateral epicondylitis. | ||
Medical condition: The epicondylitis is an overuse injury, in most cases, is a self-limited course and responds well to conservative treatment. Its etiology is degenerative and is related to a repetitive overuse and ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002473-23 | Sponsor Protocol Number: B9E-XM-O421 | Start Date*: 2005-03-24 |
Sponsor Name:Dr. Amalia Velasco | ||
Full Title: PHASE II TRIAL OF THE SEQUENTIAL ADMINISTRATION OF COMBINATIONS OF GEMCITABINE-CISPLATIN AND CARBOPLATIN-PACLITAXEL FOR THE TREATMENT OF PATIENTS WITH ADVANCED CARCINOMA OF THE OVARY WITH SUB-OPT... | ||
Medical condition: The Phase II trial will be performed on a population of patients with a histological or cytological diagnosis of ovarian cancer (any histological type), at stages IIIB, IIIC, IV or primary peritone... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-003230-22 | Sponsor Protocol Number: CICL670AIT07 | Start Date*: 2008-11-04 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: Multicenter, open label, prospective study to evaluate the efficacy and safety of deferasirox 30 mg/kg/day for 52 weeks, in transfusion-dependent β-thalassemic patients with cardiac MRI ... | |||||||||||||
Medical condition: cardiac iron overload | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007515-33 | Sponsor Protocol Number: Mel-Swe-01 | Start Date*: 2009-08-13 | ||||||||||||||||
Sponsor Name:SentoClone AB | ||||||||||||||||||
Full Title: A multi-centre, two-arm, randomized, open, phase II study of adaptive design investigating SentoClone® compared to reference treatment in advanced malignant melanoma | ||||||||||||||||||
Medical condition: Surgically incurable stage III or IV malignant melanoma. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001114-17 | Sponsor Protocol Number: WA19923 | Start Date*: 2007-12-12 |
Sponsor Name:F. Hoffmann-La Roche Limited | ||
Full Title: A Mechanism of Action study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) on lipids, arterial stiffness, and markers of atherogenic risk in patients with moderate to seve... | ||
Medical condition: Rheumatoid Arthritis (RA) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: Removed from public view |
EudraCT Number: 2010-022166-27 | Sponsor Protocol Number: CBGG492A2210 | Start Date*: 2010-11-29 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo- controlled, cross-over, proof of concept study comparing the effects of both single dose and repeated dosing treatment for 2 weeks of BGG492 in p... | |||||||||||||
Medical condition: indication “tinnitus”. condition: patients with chronic subjective tinnitus. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000241-39 | Sponsor Protocol Number: BAY86-9766/16728 | Start Date*: 2013-07-26 |
Sponsor Name:Bayer HealthCare AG | ||
Full Title: A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in combination with sorafenib as first line treatment in patients with RAS mutant Hepato... | ||
Medical condition: KRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) CZ (Completed) GB (Completed) DE (Completed) BE (Completed) IT (Completed) HU (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-008376-14 | Sponsor Protocol Number: COD_REG_46_DGR _13751_07 | Start Date*: 2009-02-24 | |||||||||||
Sponsor Name:AZIENDA ASL BRESCIA | |||||||||||||
Full Title: A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF COMBINED TREATMENT OF GUGGULU AND TRIPHALA FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND OVERWEIGHT IN SUB... | |||||||||||||
Medical condition: high blood cholesterol overweight | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020973-18 | Sponsor Protocol Number: L00006CP405 | Start Date*: 2011-03-01 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: “Effect of treatment with ossein-hydroxyapatite compound on the time of fracture-healing”. A prospective, multicenter, double-blind, randomised, placebo controlled clinical trial. | |||||||||||||
Medical condition: Wrist fracture | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
